IP Library Granted Patent US 46,860
Granted Patent E1
US 46,860 · App. 15/203,558 · Granted May 22, 2018

Recombinant cell clones having increased stability and methods of making and using the same

Inventors: Manfred Reiter (Vienna, AT); Wolfgang Mundt (Vienna, AT); Friedrich Dorner (Vienna, AT)
Assignees: Baxalta Incorporated; Baxalta GmbH
C12N5/0075C12N5/0043C12N2500/32C12N2500/38C12N2500/46C12N2500/50C12N2500/76C12N2531/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 46,860
App. No.
15/203,558
Granted
May 22, 2018
Kind
E1
Abstract

Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.

Claims (27)

1. A method for obtaining a stable recombinant mammalian cell clone that produces a recombinant product and is stable under production conditions in serum- and protein-free medium for at least 40 generations, the method comprising:

providing a recombinant original mammalian cell clone, wherein the recombinant original mammalian cell clone has a selection marker,

cultivating the recombinant original cell clone on serum-containing medium,

adapting the cells to serum- and protein-free medium with neither selection pressure for the selection marker nor selection for a polypeptide factor that replaces serum components,

testing the cell culture after adaptation for stable product-producers with neither selection pressure for the selection marker nor selection for a polypeptide factor that replaces serum components, and

cloning a stable product-producer-cell clone in serum- and protein-free conditions with neither selection pressure for the selection marker nor selection for a polypeptide factor that replaces serum components.

2. The method according to claim 1 , wherein the stable product-producer cell clone obtained is present in isolated form after the step of cloning.

3. The method according to claim 1 , wherein the recombinant cell clone comprises a nucleic acid encoding a recombinant polypeptide or protein.

4. The method according to claim 1 , wherein the recombinant product is Factor VIII.

5. The method according to claim 1 , wherein the recombinant product is Factor IX.

6. The method according to claim 1 , wherein the recombinant product is Factor VII.

7. The method according to claim 1 , wherein the recombinant product is von Willebrand factor (vWF).

8. The method according to claim 1 , wherein the original mammalian cell clone is a CHO cell clone.

9. A method for preparing a recombinant product, the method comprising:

culturing a stable recombinant mammalian cell clone that produces a recombinant product, wherein the cell clone is stable in serum- and protein-free medium for at least 40 generations with neither selection pressure for a selection marker nor selection pressure for an amplification marker in the cell clone, and expressing the recombinant product in serum- and protein-free medium so as to obtain a cell culture; and

recovering the expressed recombinant product from the cell culture, wherein the recombinant product is selected from the group consisting of: Factor VIII, Factor IX, Factor VII, and von Willebrand Factor (vWF).

10. The method according to claim 9, wherein the stable recombinant mammalian cell clone is a CHO cell clone.

11. The method according to claim 9, wherein the serum- and protein-free medium comprises one or more amino acids selected from the group consisting of: L-asparagine, L-cysteine, L-cystine, L-proline, L-tryptophan and L-glutamine.

12. The method according to claim 9, wherein the serum- and protein-free medium comprises soybean peptone having a molecular weight of ≤1000 Dalton.

13. The method according to claim 9 further comprising

providing a stable recombinant mammalian cell clone that expresses a recombinant product and is stable in serum- and protein-free medium for at least 40 generations with neither selection pressure for a selection marker nor selection pressure for an amplification marker in the cell clone.

14. The method of claim 9, wherein the stable recombinant mammalian cell clone is produced by:

providing a recombinant original mammalian cell clone, wherein the recombinant original mammalian cell clone has a selection marker and an amplification marker,

cultivating the recombinant original cell clone on serum-containing medium to create a cell culture,

adapting the cell culture to serum- and protein-free medium with neither selection pressure for the selection marker nor selection pressure for the amplification marker,

testing the cell culture after adaptation for stable product-producers with neither selection pressure for the selection marker nor selection pressure for the amplification marker, and

isolating a stable product-producer-cell clone in serum- and protein-free conditions with neither selection pressure for the selection marker nor selection pressure for the amplification marker to obtain a stable recombinant mammalian cell clone.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016
From: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 040231/0990 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016
From: BAXTER INNOVATIONS GMBH
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 040567/0848 →
CHANGE OF NAME Recorded Nov 4, 2016
From: BAXTER AKTIENGESELLSCHAFT
To: BAXTER EASTERN EUROPE VERTRIEBS GMBH
Reel/Frame 040569/0383 →
CHANGE OF NAME Recorded Nov 4, 2016
From: BAXTER EASTERN EUROPE VERTRIEBS GMBH
To: BAXTER TRADING GMBH
Reel/Frame 040569/0387 →
CHANGE OF NAME Recorded Nov 4, 2016
From: BAXTER TRADING GMBH
To: BAXTER INNOVATIONS GMBH
Reel/Frame 040569/0391 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2016
From: REITER, MANFRED; MUNDT, WOLFGANG; DORNER, FRIEDRICH
To: BAXTER AKTIENGESELLSCHAFT
Reel/Frame 040155/0171 →
Priority Claims (1)
AT 1073/97 · Jun 20, 1997 · national
Continuity (8)
Reissue 12986111 · Jan 6, 2011
Division 14567942 · Dec 11, 2014
Reissue 12986111 · Jan 6, 2011
Continuation 12488441 · Jun 19, 2009
Continuation 11123362 · May 6, 2005
Continuation 10170661 · Jun 12, 2002
Continuation 09324612 · Jun 2, 1999
Continuation In Part 09100253 · Jun 19, 1998